 cyclophosphamid cisplatin versu cyclophosphamid doxorubicin cisplatin chemotherapi ovarian carcinoma meta-analysi ovarian cancer meta-analysi project random clinic trial cyclophosphamid cisplatin CP versu cyclophosphamid doxorubicin cisplatin cap signific surviv differ treatment ovarian carcinoma patient trial meta-analysi signific surviv benefit cap addit signific advantag cap frequenc neg second-look laparotomi cap CP dose intens cap CP trial unresolv benefit cap dose intens extent doxorubicin interpret direct chemotherapi ovarian carcinoma